Clinical Scorecard: Editorial: Addressing Antimicrobial Resistance and Treatment Strategies in Severely Ill Patients, Volume II

At a Glance

Key Highlights

• MDR pathogens infections are a pressing challenge in critically ill patients.
• Colistin sulfate shows a lower risk of acute kidney injury compared to polymyxin B.
• Adjunctive aerosolized polymyxin B improves microbial eradication in severe pneumonia.
• Therapeutic drug monitoring enhances dosing accuracy for daptomycin in critically ill patients.
• Cold atmospheric-pressure plasma effectively inactivates MDR pathogens on hospital surfaces.

Guideline-Based Recommendations

Diagnosis

• Utilize precision therapeutic drug monitoring for accurate dosing.

Management

• Consider inhaled polymyxins as an adjuvant therapy for severe pneumonia.

Monitoring & Follow-up

• Implement AUC-guided dosing for vancomycin and monitor daptomycin levels.

Risks

• Be aware of the increased risk of acute kidney injury with certain antibiotics.

Patient & Prescribing Data

Patients with multidrug-resistant infections in critical care settings

Loading doses and combination therapies are critical for effective treatment.

Clinical Best Practices

• Adopt individualized antibiotic dosing based on pharmacokinetic and pharmacodynamic insights.
• Standardize guidelines for treatment of rare pathogens.

Related Resources & Content

• Research Topic on Antimicrobial Resistance